Lung tumor delineation is frequently performed using 3D positron emission tomography (PET)/computed tomography (CT), particularly in the radiotherapy treatment planning position, by generating an internal target volume (ITV) from the slow acquisition PET. We investigate the dosimetric consequences of stereotactic ablative body radiotherapy (SABR) planning on 3D PET/CT in comparison with gated (4D) PET/CT. Methods: In a prospective clinical trial, patients with lung metastases were prescribed 26 Gy single-fraction SABR to the covering isodose. Contemporaneous 3D PET/CT and 4D PET/CT was performed in the same patient position. An ITV was generated from each data set, with the planning target volume (PTV) being a 5-mm isotropic expansion. Dosimetric parameters from the SABR plan derived using the 3D volumes were evaluated against the same plan applied to 4D volumes. Results: Ten lung targets were evaluated. All 3D plans were successfully optimized to cover 99% of the PTV by the 26 Gy prescription. In all cases, the calculated dose delivered to the 4D target was less than the expected dose to the PTV based on 3D planning. Coverage of the 4D-PTV by the prescription isodose ranged from 74.48% to 98.58% (mean of 90.05%). The minimum dose to the 4D-ITV derived by the 3D treatment plan (mean = 93.11%) was significantly lower than the expected dose to ITV based on 3D PET/CT calculation (mean = 111.28%), p < 0.01. In all but one case, the planned prescription dose did not cover the 4D-PET/CT derived ITV. Conclusions: Target delineation using 3D PET/CT without additional respiratory compensation techniques results in significant target underdosing in the context of SABR.
R espiratory motion is known to introduce a potential risk of inadequate target coverage in the setting of radiotherapy for lung tumors. To mitigate this risk, the use of respiratorygated (4D) computed tomography (CT) is increasingly prevalent to account for respiratory-induced tumor excursion. 1 More recently, the use of simulation positron emission tomography (PET)/CT in the radiotherapy treatment planning position has enabled more accurate delineation of thoracic malignancies by overcoming registration errors normally introduced when planning using a simulation CT scan fused to a separately captured diagnostic. 2 In many centers, PET/CT scans acquired in the radiotherapy treatment position are performed without compensating for respiration on the assumption that this slow acquisition scan, which can take up to 30 minutes to acquire, may adequately capture respiratory induced tumor excursion across many breathing cycles. However, the intensity of the PET signal varies according to the ventilatory pattern and may underestimate the range of tumor excursion depending on patient specific breathing patterns. 3 Stereotactic ablative body radiotherapy (SABR) is a high precision radiotherapy technique characterized by sharp dose gradients and tight tumor margins. In the context of SABR, it is plausible that inaccurate target delineation may result in significant reduction in dose delivered to the tumor. The hypothesis of this study is that target delineation using slow acquisition 3D PET/CT when compared with 4D PET/ CT will result in an increased risk of geographic miss using SABR. The primary aim is to assess the dosimetric impact of radiotherapy planning using conventional 3D PET/CT in comparison with 4D PET/CT.
MATERIALS AND METHODS
As part of an independent ethics board approved prospective clinical trial (Universal Trial Number U1111-1145-0751), consecutive patients with peripheral lung metastasis were enrolled. Eligibility was defined as patients with no more than 1 to 2 18 F-FDG-PET avid pulmonary metastases with a maximum tumor diameter of less than 5 cm. Tumors were peripherally located beyond the exclusion envelope of 2 cm from central airways as defined by Timmerman et al. 4 
PET/CT Acquisition
Patients sequentially completed both a standard whole body PET/CT and a 4D PET/CT scan in a default radiotherapy planning position using the radiotherapy palette and head rest with their arms raised. Patients were not given any breathing coaching. All trial-related PET scans were performed on a GE-Discovery 690 PET/CT scanner (GE Medical Systems Milwaukee, WI). A free-breathing PET/CT scan was acquired first and took approximately 20 minutes. Immediately after the completion, a 4D-CT scan was acquired centered over the lesion of interest. Ventilation was allowed to stabilize and recorded using the Varian Real-Time Patient Monitoring (RPM) system (Palo Alto, CA). A step and shoot 4D-CT scan was performed and followed by a 10-minute list-mode PET acquisition while recording the patient breathing trace. The GE automatic phase matching software was used to process the 4D-PET/CT scan into 10 bins based on a percentage of the respiratory cycle (i.e., 0%, 10%, 20%, etc.). A representative example of sequential 3D and 4D PET/CT acquisition is given in Figure 1 . From the respiratory correlated CT data, a maximum intensity projection (MIP) CT data set was produced by the GE motion match software. Using the MIM Maestro software (MIM 5.4.4, MIM Software Inc., Cleveland, OH), an equivalent PET MIP data set was reconstructed from the respiratory correlated PET data. 5 This PET (MIP) image demonstrates the maximum PET avidity of each voxel across the respiratory cycle. A CT average (AVG) data set was reconstructed from the 4D-PET/CT data, in which the density of each voxel is represented as the average density of that voxel across all respiratory phases. All PET and CT data were reconstructed with a slice thickness of 3.75 mm.
Target Delineation
Image sets were imported in CMS Focal for the purpose of target volume and critical structure delineation. A single experienced thoracic radiation oncologist (D.L.B.) independently delineated both 3D and 4D targets at separate sittings. Manual contouring was performed using a protocol found to be highly reproducible for target delineation as previously published. 6 In delineating target volumes, the internal target volume (ITV) concept was used. A 3D-ITV was delineated using 3D-CT and 3D-PET data sets. For the purposes of planning, the 3D-PET/CT was assumed to produce a target volume inclusive of respiratory motion, because of the long acquisition time of the PET component. A 4D-ITV was delineated using 4D-CT (MIP) and 4D-PET (MIP). Standardized lung window/level settings (1700 ± 300) were used for the CT data sets. After target delineation, the 3D-CT and 4D-CT (MIP) were fused to 4D-PET/CT (AVG). As the 3D and 4D data sets were acquired sequentially without patient repositioning, the fusion was based on the shared DICOM origin of the data sets and verified through visual assessment. After image fusion, the 3D-ITVs and 4D-ITVs were copied from their respective data sets to the 4D-PET/CT (AVG) for the purpose of treatment planning and dose calculation. A uniform expansion of 5 mm was applied to both 3D-ITV and 4D-ITV to create the 3D-planning target volume (3D-PTV) and 4D-PTV, respectively.
Treatment Planning
Treatment planning was performed using CMS XiO (Elekta, Stockholm, Sweden) by a single experienced radiation therapist (B.C.). Treatment plans consisted of 8 to 12 fields (median 10) as previously described, 7 with multi-leaf collimator (MLC) apertures adapted to fit the 3D-PTV using autoport functionality. Dose was prescribed to the covering 80% isodose. MLC apertures were individually optimized both to achieve target coverage and to maximize dose conformity to the PTV. This optimization included use of negative MLC margins. Dose calculations were performed using a Superposition/Convolution calculation algorithm and a 0.2 cm calculation grid. Beam weightings and MLC apertures were optimized to achieve coverage of the 3D-PTV equal to D99, 100%.
Once the plan had been optimized to achieve coverage of the 3D-PTV, the coverage of the 4D-PTV achieved with this plan was evaluated using dose volume histogram analysis. The percentage of 4D-PTV enclosed within the prescription isodose was recorded, along with the absolute minimum dose received by the 4D-PTV and 4D-ITV. Dosimetric coverage between 3D and 4D volumes was compared using two-sided paired t-tests. The minimum biological effective dose (BED) 8 achieved at the periphery of the PTV was calculated based on the 4D volumes using an alpha/beta ratio of 10 Gy and compared with the expected BED 10 Gy of 94 Gy.
RESULTS
Ten peripheral lung metastases in eight patients were planned for a single fraction 26 Gy of SABR. Distribution of targets was as follows; one target in the right upper lobe, two in the left upper lobe, two in the right middle lobe, two targets in the right lower lobe, and two in the left lower lobe. The right middle lobe tumors were grouped with the right upper lobe tumors for the remainder of the analysis. The absolute volumes of the 3D-PTV (mean 16.85 cc) and 4D-PTV (mean 18.43 cc) were not significantly different, p is equal to 0.51, Table 1 .
In producing plans optimized to the 3D-PTV, all plans were successfully optimized to achieve the objective of the dose to 99% of the PTV (D99), 100%. Coverage of the 4D-PTV by the 3D derived treatment plan was significantly lower, with a mean of 90.05% (range 74.48-98.58%) of the 4D-PTV enclosed within the prescription isodose. The resultant minimum BED 10 Gy at the periphery of the 4D PTV volume was a mean of 57.61 Gy (range 33.29-71.70 Gy). The percentage of 4D-PTV enclosed within the prescription isodose, minimum 4D-PTV dose, and resultant BED 10 Gy for each case is reported in Table 2 . Coverage of the 4D-PTV was dependent upon the anatomical location of the target within the lung. Target coverage with the prescription dose was significantly less in lower lobe tumors (mean = 83.92%) when compared with upper lobe (mean = 96.18%), p is equal to 0.01. In all but one case, the 4D-ITV received less than the prescription isodose. PET/CT, positron emission tomography/computed tomography; ITV, internal target volume.
In addition to coverage of the PTV, the minimum dose received by both the 3D-PET/CT and 4D-PET/CT derived ITVs was recorded, with results reported in Table 3 . The minimum dose to the 4D-ITV (mean = 93.11%) derived by the 3D treatment plan was uniformly lower than the expected dose to ITV based on 3D PET/CT calculation (mean = 111.28%), p < 0.01. Similar to the PTV coverage, the minimum dose to ITV was significantly less in lower lobe tumors (mean = 86.77%) when compared with upper lobe (mean = 99.46%), p is equal to 0.01.
DISCUSSION
In this study, we demonstrate that the delineation of pulmonary targets using 3D PET/CT imaging results in significant risk of marginal miss. In all cases, the calculated dose delivered was less than the expected dose to the PTV when compared with target volumes generated from 4D PET/CT, resulting in significantly less than expected biological dose at the target periphery. When applying 3D-PET/CT based treatment plan to 4D-PET/CT volumes, all plans failed to meet the D99 equal to 100% PTV coverage objective. A similar but less marked dosimetric impact was observed for the ITV. In all but one case, the prescription dose from the 3D derived treatment plan prescription did not cover the ITV derived from the 4D-PET/CT. This phenomenon was largely observed in tumors situated in the lower lobes, which are more prone to ventilation-induced motion error, and in contrast, the upper lobe tumors maintained an average minimum dose of 99.46% to the ITV.
Simulation 3D PET/CT in the radiotherapy treatment position is an attractive proposition for the delineation of lung tumors because of the minimization of registration errors across functional and anatomical data sets. When defining target volumes the information obtained from the two imaging modalities provides complementary information about both tumor structure (CT) and physiology (PET). 9 Despite the fact that 3D PET/ CT acquisition inherently covers many more respiratory cycles than is routinely captured with conventional respiratory-gated radiotherapy simulation techniques, our study demonstrates that target coverage is inadequate for SABR when delineating using 3D techniques. This is particularly evident for lower lobe tumors. Our findings are consistent with previous phantom 3, 5 and clinical studies investigating the impact of target delineation using 3D PET/CT when compared with 4DCT 10,11 or 4D PET/CT [12] [13] [14] [15] [16] acquisition techniques. Importantly, in this study, we demonstrate that these differences in delineation result in significant dosimetric consequences in the context of radiotherapy treatment delivery.
There are several limitations of this study. The use of 4D-PET/CT over conventional 4DCT in SABR planning is not directly compared in this study. However, 4D-PET/CT may be an attractive modality as it is a single-acquisition technique that provides respiratory compensated target definition for radiotherapy planning, functional tumor information, and screening of occult distant widespread metastases.
This study only includes patients with lung metastases, and therefore, these findings may not be directly extrapolated to patients with primary lung cancer and preexisting lung disease, which might impact on tumor mobility. We recommend that 3D-PET/CT is not used to define the target volume in lung SABR because of the significant risk of geographic miss.
